Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) CFO Kamran Alam sold 33,000 shares of the stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $2.33, for a total value of $76,890.00. Following the completion of the sale, the chief financial officer now directly […]
Operator: Thank you for standing by. This is the conference operator. Welcome to the Taysha Gene Therapies First Quarter 2023 Earnings Conference Call.
Taysha Gene Therapies faces potential delisting of its shares the latest in a series of setbacks that include scrapping a $75-million manufacturing facility in Durham, NC.
Operator: Greetings, and welcome to the Taysha Gene Therapies Fourth Quarter and Full-Year 2022 Earnings Call. At this time, all participants are in a listen-only mode.